PROTALIX BIOTHERAPEUTICS, INC. COMMON STOCK (AM:PLX)

View All ReportsStreetInsider.com Reports on PLX

Feb 2, 2010 07:33 AM Protalix BioThera (PLX) to Supply U.S. FDA with Additional Data Tied to Taliglucerase Alfa NDA

Jan 25, 2010 10:54 AM Morning Movers 1/25: SMTX, NBS, ERI, KFS, PVTB, CADC Higher; PARD, SNEN, BBX, PCBC Lower

Jan 14, 2010 04:12 PM Protalix (PLX) Gets Orphan Drug Recommendation on Taliglucerase Alfa

Jan 13, 2010 07:38 AM Protalix BioTherapeutics (PLX) Taliglucerase Alfa Gets Recommendation from EMEA (PFE)

Dec 17, 2009 09:22 AM Protalix BioTherapeutics (PLX) Names Sandra lauterbach to VP - Sales and Commercial Affairs

View All Press ReleasesCompany Press Releases on PLX

Feb 4, 2010 07:30AM Protalix Announces Presentation of Phase III Taliglucerase Alfa Data at WORLD Lysosomal Disease Network

Feb 2, 2010 05:30AM Protalix Announces NDA Submission Update for taliglucerase alfa for the Treatment of Gaucher Disease

Jan 13, 2010 07:30AM European Medicines Agency's COMP Adopts Positive Opinion for the Orphan Drug Designation for Protalix's taliglucerase alfa

Dec 17, 2009 08:30AM Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs

StreetInsider Reports on PLX by Category

• Analyst Ratings
• Mergers and Acquisitions
• Earnings
• Guidance
• Stock Buybacks
• Dividends
• Retail Sales
• Management Changes
• Insider Trades
• View More Categories

View All BlogsBlogs on PLX

Feb 8, 2010 04:14 AM GlaxoSmithKline, Poniard, Protalix Provide Biotech's Latest Mishaps

Feb 2, 2010 12:16 PM Another Setback for Protalix

Dec 30, 2009 02:43 AM My 10 Picks for 2010's Tech Revolution

Nov 17, 2009 09:00 AM Lumizyme Rejected Again: Downgrading Genzyme Recommendation from Buy to Hold

Nov 16, 2009 09:37 AM Insiders Still Quite Bearish on Their Own Companies

View All FilingsSEC Filings on PLX

Feb 9, 2010 05:25PM Form 4 Protalix BioTherapeutics For: Feb 07 Filed by: Lauterbach Sandra Leigh

Feb 5, 2010 07:35AM Form 8-K Protalix BioTherapeutics For: Feb 04

Feb 2, 2010 07:01AM Form 8-K Protalix BioTherapeutics For: Feb 02

Jan 14, 2010 04:07PM Form 8-K Protalix BioTherapeutics For: Jan 13

Dec 22, 2009 04:31PM Form 8-K Protalix BioTherapeutics For: Dec 17

Comments on recent PLX articles

M. Smernov
on Nov 28, 2009
at 05:59 AM The 20K foot view of PLX Uplyso will be the first bio-generic, but the real value is in the validation of the concept that PLX will be able to copy a lot of existing patented bio drugs using their pro-cell technology and not violate patent laws. This could be THE game changer in bio-drugs. I am long PLX, and price targets are meaningless. All I can say is that if Uplyso gets final approval, the stock will move so fast is will make your head swim.
Article: Canaccord Adams Maintains a 'Buy' on Protalix BioTherapeutics (PLX); Cerezyme Supply on Track, See More Uplyso EAP Uptake

a yahav
on Nov 27, 2009
at 11:57 AM PLX target price With their estimate of a minimum of 15% market share the target price should be at least about 26 $ and not 13!
Article: Canaccord Adams Maintains a 'Buy' on Protalix BioTherapeutics (PLX); Cerezyme Supply on Track, See More Uplyso EAP Uptake

Ken
on Nov 19, 2009
at 10:11 AM PLX Why is this stock down over the last week?
Article: Protalix BioThera (PLX) May Have a Winner with Gaucher Drug prGCD

Land
on Nov 10, 2009
at 05:36 PM Takeover speculaton When one reads the statement that accompanied the Q3 financials, it is clear that protalix is much more than a one trick pony. Not only is a drug now ready for finai approval for Gauchers disease with potential annual sales of $120 to 200,000,000 but the company is making excellent progress on another enzyme treatment, a biological weapons defense medication, a rhematoid arthritis treatment, and at least one other drug for an undisclosed ailment. All are bio-idential to existing drugs (except the bio-defense one) with existing markets so the clinical trials a little less complicated. They might partner withanother company to license the basic method of production they should continue to develop and sel leverything they can produce. If the bio-defense medication is effective, it willl be ordered by every army in the world. If the other drugs are effective, their sales could easily be (like Gensyme) in the billions. If antoher company wants everything including the entire pipeline, the price has to be very very high.
Article: Canaccord Adams Reiterates a 'Buy' on Protalix BioTherapeutics (PLX)

Iki
on Sep 2, 2009
at 05:15 PM $10 is under esstimation !! Would like to emphsize that the holders can easily get more than $1B for FDA approved company, while $1B represent $13 of 76MM outstanding stocks. Profesionals can tell that the holder will not give up the company for much more...
Article: Hapoalim Securities Initiates Coverage on Protalix BioTherapeutics (PLX) with an Outperform; Attractive Entry Point

Comments on PLX

No comments are currently available.

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?